Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: celecoxib

First Posted Date: 2003-01-27

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 21

Registration Number: NCT00020878

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

Interventions: Biological: dendritic cell-MART-1 peptide vaccine

First Posted Date: 2003-01-27

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 28

Registration Number: NCT00039325

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Biological: trastuzumab
Drug: erlotinib hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2020-10-08

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 27

Registration Number: NCT00033514

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Adult
Solid Tumor

First Posted Date: 2003-01-27

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 16

Registration Number: NCT00052273

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery

Phase 2

Completed

Conditions: Liver Cancer

Interventions: Biological: bevacizumab

First Posted Date: 2003-01-27

Last Posted Date: 2020-09-01

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT00049322

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Comparison of Screening Tests in Detecting Cervical Neoplasia

Not Applicable

Completed

Conditions: Cervical Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 15

Registration Number: NCT00039312

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Sirolimus in Treating Patients With Glioblastoma Multiforme

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: Rapamycin
Procedure: Surgery
Procedure: Supportive Care

First Posted Date: 2003-01-27

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 13

Registration Number: NCT00047073

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer

Phase 1

Completed

Conditions: Colorectal Cancer
Pancreatic Cancer
Prostate Cancer
Esophageal Cancer
Kidney Cancer
Lung Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-08

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00004879

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma

Phase 1

Completed

Conditions: Melanoma

Interventions: Biological: dendritic cell-MART-1 peptide vaccine
Procedure: leukapheresis

First Posted Date: 2003-01-27

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00005617

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: vinorelbine ditartrate

First Posted Date: 2003-01-27

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 14

Registration Number: NCT00003963

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy